Janux Therapeutics (JANX) Stock Forecast & Price Target

$18.68 +0.08 (+0.43%)

Closing price 08/25/2026 04:00 PM Eastern

Extended Trading

$17.93 -0.75 (-4.04%)

As of 06:46 AM Eastern

Compare

Janux Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 15 Analyst Ratings

Sell
2

Hold
2

Buy
11

Based on 15 Wall Street analysts who have issued ratings for Janux Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 2 have given a sell rating, 2 have given a hold rating, 10 have given a buy rating, and 1 has given a strong buy rating for JANX.

Consensus Price Target

$36.46
95.19% Upside

According to the 15 analysts' twelve-month price targets for Janux Therapeutics, the average price target is $36.46. The highest price target for JANX is $100.00, while the lowest price target for JANX is $14.00. The average price target represents a forecasted upside of 95.19% from the current price of $18.68.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for JANX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Janux Therapeutics and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

JANX Analyst Ratings Over Time

Type	Current Forecast 8/26/25 to 8/26/26	1 Month Ago 7/27/25 to 7/27/26	3 Months Ago 5/28/25 to 5/28/26	1 Year Ago 8/26/24 to 8/26/25
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	10 Buy rating(s)	9 Buy rating(s)	9 Buy rating(s)	10 Buy rating(s)
Hold	2 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	1 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$36.46	$38.08	$45.85	$86.90
Forecasted Upside	95.19% Upside	144.59% Upside	211.03% Upside	267.60% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy

JANX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

JANX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Janux Therapeutics Stock vs. The Competition

Type	Janux Therapeutics	Healthcare Companies	Broader Market
Consensus Rating Score	2.67	2.30	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	95.19% Upside	903.93% Upside	12.47% Upside
News Sentiment Rating	Positive News See Recent JANX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
8/24/2026	Wolfe Research 4 of 5 stars	Kalpit Patel Not Rated	Upgrade	Peer Perform ➝ Outperform	$23.00	+32.26%
8/24/2026	TD Cowen 3 of 5 stars		Upgrade	Strong-Buy
8/7/2026	Stifel Nicolaus 4 of 5 stars		Set Target		$35.00	+119.41%
8/7/2026	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brad Canino Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$58.00 ➝ $55.00	+244.65%
7/20/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Sell (D-)
6/25/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Supawat Thongthip Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$80.00 ➝ $26.00	+75.30%
5/11/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$22.00	+51.57%
5/8/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kelsey Goodwin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$30.00 ➝ $26.00	+83.84%
5/8/2026	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robert Driscoll Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$45.00 ➝ $36.00	+151.84%
4/28/2026	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boris Peaker Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$50.00 ➝ $28.00	+94.92%
It’s not about Greenland (Ad) The petrodollar arrangement that anchored the US dollar for 50 years quietly expired in June 2024. Since then, China has cut its Treasury holdings by 45% from their peak, and BRICS nations offloaded $47 billion of American debt in a single month. The Trump administration has responded with a $12 billion critical minerals stockpile called Project Vault, equity stakes in miners like MP Materials and Lithium Americas, and a push to secure resources from Greenland to Ukraine. Porter Stansberry lays out the full story in a new documentary, including five companies positioned at the chokepoints of what he calls Trump's New Dollar. Watch the full documentary before December's economic summit in Miami
4/20/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Etzer Darout Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Overweight ➝ Underweight	$29.00 ➝ $14.00	-11.50%
4/15/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Dai Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$57.00 ➝ $15.00	-1.57%
2/27/2026	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Josh Schimmer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$150.00 ➝ $100.00	+639.97%
1/20/2026	Clear Str Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
12/2/2025	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Swayampakula Ramakanth Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$70.00 ➝ $45.00	+32.39%
12/2/2025	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Geoff Meacham Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$58.00 ➝ $49.00	+44.16%
7/11/2025	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sean McCutcheon Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform	$65.00	+153.81%
2/28/2025	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	George Farmer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Sector Perform	$62.00 ➝ $41.00	+24.66%
1/10/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
12/27/2024	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	O. Mccammon Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy
12/3/2024	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Outperform	$79.00 ➝ $91.00	+46.09%
12/3/2024	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$82.00 ➝ $100.00	+148.88%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 06:57 AM ET.

JANX Forecast - Frequently Asked Questions

According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Janux Therapeutics is $36.46, with a high forecast of $100.00 and a low forecast of $14.00.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Janux Therapeutics in the last twelve months. There are currently 2 sell ratings, 2 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" JANX shares.

According to analysts, Janux Therapeutics's stock has a predicted upside of 95.19% based on their 12-month stock forecasts.

Over the previous 90 days, Janux Therapeutics's stock had 2 upgrades by analysts.

Janux Therapeutics has been rated by research analysts at Guggenheim, Stifel Nicolaus, TD Cowen, Truist Financial, Weiss Ratings, and Wolfe Research in the past 90 days.

Analysts like Janux Therapeutics more than other "healthcare" companies. The consensus rating for Janux Therapeutics is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how JANX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Janux Therapeutics Recommendations

MarketBeat monitors more than a dozen sources for Janux Therapeutics analyst ratings, with the most recent rating issued on 8/24/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Janux Therapeutics (JANX) Stock Forecast & Price Target

Janux Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

JANX Analyst Ratings Over Time

JANX Analyst Recommendations By Month

JANX Price Targets by Month

Janux Therapeutics Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

JANX Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Janux Therapeutics Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Janux Therapeutics (JANX) Stock Forecast & Price Target

Janux Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

JANX Analyst Ratings Over Time

JANX Analyst Recommendations By Month

JANX Price Targets by Month

Janux Therapeutics Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

JANX Forecast - Frequently Asked Questions

What is Janux Therapeutics' forecast for 2026?

Should I buy or sell Janux Therapeutics stock right now?

Does Janux Therapeutics's stock price have much upside?

Has Janux Therapeutics been upgraded by Wall Street analysts recently?

What analysts cover Janux Therapeutics?

Do Wall Street analysts like Janux Therapeutics more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Janux Therapeutics Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools